Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 532
- Registration Number
- NCT02008266
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1225
- Registration Number
- NCT02008227
- Locations
- πΊπΈ
Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
πΊπΈRoy & Patricia Disney Family Cancer Center, Burbank, California, United States
πΊπΈSt. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Phase 2
Completed
- Conditions
- Urinary Tract Cancer
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT02006667
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT02006706
OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
Phase 3
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 252
- Registration Number
- NCT02005562
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02005484
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 389
- Registration Number
- NCT02005471
- Locations
- π§πͺ
Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium
πΊπΈHuntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States
π¦πΊRoyal Adelaide Hospital, Adelaide, South Australia, Australia
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02005549
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT02004093
A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO6895882
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT02004106
- Locations
- π³π±
VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands
πͺπΈHospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
π³π±Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
Β© Copyright 2025. All Rights Reserved by MedPath